Global Information
회사소개 | 문의 | 비교리스트

세계의 제네릭 의약품 시장

Global Markets for Generic Drugs

리서치사 BCC Research
발행일 2021년 05월 상품코드 1006811
페이지 정보 영문 155 Pages 배송안내
가격
US $ 5,500 ₩ 7,813,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,600 ₩ 9,375,000 PDF (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,920 ₩ 11,251,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 9,504 ₩ 13,501,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 제네릭 의약품 시장 Global Markets for Generic Drugs
발행일 : 2021년 05월 페이지 정보 : 영문 155 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 제네릭 의약품 시장 규모는 2020년 4,116억 달러에서 2025년까지 6,503억 달러에 달할 것으로 예측됩니다.

또한 2020-2025년간 연평균 복합 성장률(CAGR)은 9.6%를 나타낼 전망입니다.

세계의 제네릭 의약품(Generic Drugs) 시장을 분석했으며, 제품 개요, 시장의 기본 구조, 주요 시장 성장 촉진요인 및 억제요인, 시장 규모·성장률·시장 점유율 동향 전망, 지역별·종류별 상세 동향, 최근 임상시험(파이프라인 제품 개발)과 자본거래 동향, 주요 기업 개요(총 20개사 이상), 코로나19(COVID-19)의 영향 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 요약 및 하이라이트

제3장 시장 개요

  • 서론
  • 제네릭 의약품 업계의 최근 동향
  • Roche-Bolar
  • Generics Lobby
  • ICH

제4장 코로나19(COVID-19)의 영향

  • 개요
  • 제약 업계에 대한 단기적인 영향
  • 제약 업계에 대한 장기적인 영향
  • 제네릭 의약품 시장에 대한 COVID-19의 영향
  • 공급망에 대한 영향

제5장 신제네릭 시대

  • 개요
  • 특허 절벽
  • 제네릭 의약품의 종류
  • 심플 제네릭
  • 슈퍼 제네릭
  • 바이오시밀러
  • ANDA(Abbreviated New Drug Application) 승인

제6장 제네릭 의약품 시장의 주요 문제

  • 규제 환경
  • 미국
  • 유럽연합
  • 일본
  • 바이오시밀러 규제
  • EU의 규정
  • 미국의 상황 변화
  • 사용자 요금
  • 대형 제약 기업이 채용하고 있는 방어 전략
  • 인가된 제네릭 의약품
  • 사용자 요금
  • 제네릭 의약품의 상황 변화
  • 유럽의 상황
  • 특허와 지식재산
  • 보충적 보호등록증(SPC)

제7장 세계의 제네릭 의약품 시장

  • 세계의 의약품 시장 : 브랜드 의약품과 제네릭 의약품
  • 세계의 제네릭 의약품 시장
  • 제품 클래스별 시장 기회
  • 의약품 시장 점유율 : 치료 영역별

제8장 지역별 시장 분석

  • 서론
  • 북미
  • 미국
  • 캐나다
  • 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양 국가
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 기타 유럽 국가
  • 기타 국가(RoW)

제9장 업계 동향

  • 경쟁 구도
  • 시장 동향
  • 제네릭 의약품 업계의 구조
  • 최근의 인수합병(M&A)
  • 브랜드 의약품 기업의 관여

제10장 기업 개요

  • ASPEN HOLDINGS
  • CIPLA INC.
  • FRESENIUS KABI
  • LUPIN LTD.
  • MYLAN INC.
  • PFIZER INC.
  • SANDOZ INTERNATIONAL GMBH
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

제11장 기타 국제 기업

  • AUROBINDO PHARMALTD.
  • DR. REDDY'S LABORATORIESLTD.
  • EGIS PHARMACEUTICALS PLC
  • KRKA
  • PAR PHARMACEUTICALINC.
  • STADA ARZNEIMITTEL
  • STRIDES SHASUNLTD.
  • WOCKHARDTLTD.
  • ZYDUS CADILA

제12장 부록 : 용어 및 두자어

LSH 21.06.23

List of Tables

  • Summary Table : Global Market for Generic Drugs, by Region, Through 2025
  • Table 1 : Global Market for Generic Drugs Compared with the Total Pharmaceutical Market, by Region, Through 2025
  • Table 2 : Coronavirus Reported Cases and Deaths, by Country, as of March 8, 2021
  • Table 3 : Major Recent and Upcoming Patent Expiries, 2016-2021
  • Table 4 : Sales of Brand Name Drugs Before and After Patent Expiry
  • Table 5 : Biologics with Recent or Upcoming Loss of Patent Protection
  • Table 6 : Recent Approvals of Biosimilars, 2018-2020
  • Table 7 : ANDA Approvals of Generic Drugs, by Company, 2019
  • Table 8 : Requirements for NDA and ANDA Applications
  • Table 9 : Global Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 10 : Global Market for Generic Drugs, by Top 10 Countries, Through 2025
  • Table 11 : Top 20 Generic Molecules, 2019
  • Table 12 : Global Top Selling Pharmaceuticals, 2019
  • Table 13 : Leading Anti-infective Products Sales, 2018
  • Table 14 : Leading CNS Products Sales, 2018
  • Table 15 : Leading Cardiovascular Product Sales, 2019
  • Table 16 : Leading Anti-arthritis Product Sales, 2018
  • Table 17 : Leading Respiratory Product Sales, 2018
  • Table 18 : Leading Anticancer Product Sales, 2018
  • Table 19 : U.S. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 20 : Canadian Leading Therapeutic Classes in Retail and Hospital Purchases, 2019
  • Table 21 : Canadian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 22 : Chinese Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 23 : Japanese Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 24 : Japanese Pharmaceutical Sales, by Top 25 Japanese Pharma Companies, 2018 and 2019
  • Table 25 : Indian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 26 : Leading Generic Drug Companies in India
  • Table 27 : Rest of Asia-Pacific Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 28 : French Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 29 : German Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 30 : Italian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 31 : U.K. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 32 : Leading Pharma Companies in the U.K., by Company, 2018
  • Table 33 : Spanish Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 34 : Penetration of Generic Drugs in the Pharmaceutical Market in the Rest of Europe, by Country, 2019
  • Table 35 : Rest of European Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 36 : Rest of World Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2025
  • Table 37 : Leading Generic Drug Companies, by Sales, 2019
  • Table 38 : Acronyms Used in This Report

List of Figures

  • Summary Figure : Global Market for Generic Drugs, by Region, 2018-2025
  • Figure 1 : Impact of COVID-19 on the Pharma Industry
  • Figure 2 : Trends in Global Prescription Drug Sales, 2015-2019
  • Figure 3 : Global Market Shares of Pharmaceutical Drugs, by Therapeutic Area, 2019
  • Figure 4 : Global Market Shares of Asthma Drugs, by Product Category, 2015
  • Figure 5 : Healthcare Expenditures in Major European Markets and the U.S., 2019

Highlights:

The global market for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025.

The North American market for generic drugs should grow from $135.8 billion in 2020 to $224.1 billion by 2025, at a CAGR of 10.5% for the period of 2020-2025.

Asia-Pacific market for generic drugs should grow from $171.8 billion in 2020 to $289.6 billion by 2025, at a CAGR of 11.0% for the period of 2020-2025. 

Report Scope

This report discusses the implications of all the above-mentioned trends in the context of the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets. The nature and structure of the generic drug industry is discussed, with profiles of the leading 20+ generic drug companies and an update on M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of the products involved.

Based on geography, the market has been segmented into North America, Europe, Asia-Pacific and Rest of the World. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2019 as the base year, with forecasts for 2020 through 2025. The estimated values used are based on drug manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes

  • 38 tables
  • An updated review of the global market for generic drugs
  • Analyses of the global market trends, with data from 2018-2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Highlights of current and future market potential of generic drugs along with an emphasis on the major generics issue, regulatory landscape and patent cliff within the generic drugs industry
  • COVID-19 impact (both short term vs. long term) on the global generic drugs market compared to the overall pharmaceutical industry
  • Estimation of the market size and market forecast for pharmaceuticals and generic drugs by the most important geographies and major therapeutic categories of products
  • Key M&A deals, collaborations and partnerships, licensing and manufacturing agreements, and other investment strategies within this market
  • Competitive landscape of the key players in the global generic drugs market, analysis of company sales data, and structure of the generics industry
  • Insight into the pipeline analysis of new and generic drugs and their impact on the growth of the market
  • Company profiles of the leading players operating in global generic drugs market including Aspen, Cipla, Lupin, Pfizer, Sanofi, Sun Pharmaceuticals and Teva Pharmaceuticals

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Intended Audience
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

  • Market Size and Evolution

Chapter 3 Market Overview

  • Introduction
  • Recent History of the Generic Drug Industry
  • Roche-Bolar
  • Generics Lobby
  • ICH

Chapter 4 Impact of COVID-19

  • Overview
  • Short-Term Impact on the Pharma Industry
  • Long-Term Impact on the Pharma Industry
  • Impact of COVID-19 on the Market for Generic Drugs
  • Impact on the Supply Chain

Chapter 5 The New Generics Era

  • Overview
  • The Patent Cliff
  • Types of Generic Drugs
  • Simple Generics
  • Super Generics
  • Biosimilars
  • ANDA (Abbreviated New Drug Application) Approvals

Chapter 6 Major Issues Within the Market for Generic Drugs

  • Regulatory Environment
  • U.S.
  • European Union
  • Japan
  • Regulation of Biosimilars
  • EU Provisions
  • Evolving Situation in the U.S.
  • User Fees
  • Defensive Strategies Used by Big Pharma
  • Authorized Generic Drugs
  • User Fees
  • Changing Climate for Generics
  • Situation in Europe
  • Patents and IP
  • Supplementary Protection Certificates

Chapter 7 Global Market for Generic Drugs

  • Global Pharmaceutical Market: Brand Name and Generic Drugs
  • Global Market for Generic Drugs
  • Market Opportunities by Product Class
  • Market Shares of Pharmaceutical Drugs by Therapeutic Area

Chapter 8 Market Breakdown by Region

  • Introduction
  • North America
  • U.S.
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
  • Europe
  • France
  • Germany
  • Italy
  • U.K.
  • Spain
  • Rest of Europe
  • Rest of the World

Chapter 9 Industry Trends

  • Competitive Landscape
  • Market Trends
  • Structure of the Generic Drug Industry
  • Recent Mergers and Acquisitions
  • Brand Name Company Involvement

Chapter 10 Company Profiles

  • ASPEN HOLDINGS
  • CIPLA INC.
  • FRESENIUS KABI
  • LUPIN LTD.
  • MYLAN INC.
  • PFIZER INC.
  • SANDOZ INTERNATIONAL GMBH
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

Chapter 11 Other International Companies

  • AUROBINDO PHARMA LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • EGIS PHARMACEUTICALS PLC
  • KRKA
  • PAR PHARMACEUTICAL INC.
  • STADA ARZNEIMITTEL
  • STRIDES SHASUN LTD.
  • WOCKHARDT LTD.
  • ZYDUS CADILA

Chapter 12 Appendix: Terminology and Acronyms

Back to Top
전화 문의
F A Q